本期 13F-HR 中的全部持仓，以及相对上季度的变化。
13F 持仓，最新季度
来源SEC EDGAR13F-HR
Medicxi Ventures Management (Jersey) Ltd (CIK 1715579) reported $177.4M across 3 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: PHAT ($81.0M, 45.65%), NAMS ($74.9M, 42.19%), AURA ($21.6M, 12.16%), CNTA ($0, 0.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | PHAT | PHATHOM PHARMACEUTICALS INC | $81.0M | 45.65% | 7.5M | Hold |
| 2 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $74.9M | 42.19% | 2.2M | Trimmed |
| 3 | AURA | AURA BIOSCIENCES INC | $21.6M | 12.16% | 3.0M | Hold |
| 4 | CNTA | CENTESSA PHARMACEUTICALS PLC | $0 | 0.00% | 0 | Exited |
来源：SEC 13F 申报文件 · 截至 2026-06-30